Biomarker studies in patients treated with dapagliflozin for 6 weeks showed a reduction of several tubular damage markers (kidney injury molecule-1, neutrophil gelatinase-associated lipocalin, and liver-type fatty acid binding protein), suggesting that there may indeed be some tubular alteration that might decrease tubular susceptibility to AKI [19]. Here, LCN2 is linked to acute kidney injury.